



DOX-SAA@LNP-DTPA, doxorubicin-SAA modified lipid nanoparticles-DTPA complex

Cat. No. R-LNP2

Lot. No. (See product label)

Alias	Doxorubicin-serum amyloid A modified lipid nanoparticles-diethylenetriaminepentaacetic acid complex,
Appearance	Dispersion
Molecular Formula	N/A
Solubility	Can be stably dispersed in aqueous solution to form a colloidal system
Storage	2-8°C, protected from light
Purity	95%+
Shelf Life	1 year
Shipping Condition	low temperature transport
Application	MRI contrast agent
Specification	10mg : Inquiry 20mg : Inquiry 50mg : Inquiry
Description	DOX-SAA@LNP-DTPA is a nanocomposite that integrates drug delivery, targeted transport and imaging diagnosis functions. The complex uses lipid nanoparticles (LNP) as the core carrier. With its good biocompatibility and degradability, it can efficiently encapsulate doxorubicin, effectively protect the drug activity and reduce the side effects of the drug on normal tissues. Serum amyloid A (SAA) is modified on the surface of LNP, which can specifically recognize receptors abnormally expressed on the surface of tumor cells, giving

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY

www.matexcel.com

Address: SUITE 210, 17 Ramsey Road, Shirley, NY 11967

Email: info@matexcel.com Tel: 1-631-869-4956 Fax: 1-631-910-2166



the complex the ability to actively target tumor cells, allowing doxorubicin to be accurately enriched in the tumor site. The introduction of diethylenetriaminepentacetic acid (DTPA) can not only chelate metal ions and serve as a magnetic resonance imaging (MRI) contrast agent to achieve visual diagnosis of tumor, but can also adjust the surface properties of nanoparticles and optimize their in vivo circulation performance.

Supplier

Xi'an Ruixi

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY

www.matexcel.com

Address: SUITE 210, 17 Ramsey Road, Shirley, NY 11967

Email: info@matexcel.com Tel: 1-631-869-4956 Fax: 1-631-910-2166